114 results
Page 3 of 6
8-K
EX-1.1
nl8xzpca
20 Aug 21
Entry into a Material Definitive Agreement
5:20pm
8-K
EX-99.1
wd42n1ecqoiw0bn0u pc
5 Aug 21
Athenex Provides Second Quarter 2021 Corporate and Financial Update
7:50am
8-K
EX-99.1
eoyblsn0e
6 May 21
Athenex Provides First Quarter 2021 Corporate and Financial Update
7:16am
8-K
EX-99.1
18oo8
5 May 21
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
12:00am
8-K
EX-10.1
vamqhn39kp
5 May 21
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
12:00am
8-K
EX-99.2
lz3878s cpi68pmm2i
1 Mar 21
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
7:30am
8-K
EX-99.1
o22rmp 4fo8
1 Mar 21
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
7:30am
8-K
EX-99.1
7cebn3 xj
18 Feb 21
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
9:30am
8-K
EX-10.1
gu0 x6b0sbs8ehhb9
10 Sep 20
Athenex, Inc. Announces Proposed Public Offering of Common Stock
5:24pm
424B5
8d2scpailun ivxrh
10 Sep 20
Prospectus supplement for primary offering
4:06pm
424B5
byi7hj vbkd7
8 Sep 20
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
5ldo hx5u35exx9cw88j
8 Sep 20
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
9:16am